Clinical trials

#Clinical trials #Covid-19 #RNA

CV2CoV shows improved immune protection in preclinical study 

CureVac and GSK have published preclinical data investigating immune responses as well as the protective efficacy of CureVac’s first-generation vaccine candidate, CVnCoV, and second-generation vaccine candidate, CV2CoV, against SARS-CoV-2 challenge in non-human primates.   The study, conducted in collaboration with Harvard Medical School, assessed cynomolgus macaques vaccinated… Read More

#Covid-19 #News

#Cancer research #Clinical trials #Immuno-oncology #Oncology

Belarus adds hormone-resistant prostate and breast cancers to study  

The Republic of Belarus Ministry of Health has approved expanding the ongoing clinical trial of CureLab Oncology’s Elenagen, an experimental DNA therapy, to include hormone-resistant breast cancer and hormone-resistant metastatic prostate cancer.  The decision to add two more deadly diseases to the ongoing study was based on encouraging preliminary results… Read More

#Cancer Research #News

#Biopharmaceuticals #Clinical trials #Data #Global data

New results in psoriasis pave way for potential best in class

UCB, a biopharmaceutical company, has presented new interim data from BE BRIGHT, an open-label extension (OLE) trial of an interleukin (IL)-17A/F inhibitor ‘bimekizumab’ for plaque psoriasis (PsO), at the 2021 American Academy of Dermatology (AAD) Summer Meeting. While the data are still preliminary, they strongly support a potential approval for… Read More

#News

#Clinical trials #Drug development #Drug discovery #Infectious diseases #Research

This week in drug discovery (9-13 August)

News round-up by DDW’s Megan Thomas for 9-13 August This week, DDW’s Megan Thomas has rounded up five stories which report positive data and findings from around the globe in the drug discovery sector. Preclinical data on oral polymer-based duodenal exclusion therapy Glyscend has presented data during the American… Read More

#News #Trending News

#Clinical trials

Phase IIb study initiated for non-opioid post-operative analgesic

Cali Biosciences (CaliBio) has initiated a Phase IIb study of its perioperative long-acting analgesic product CPL- 01, an extended-release injectable version of Naropin (ropivacaine hydrochloride), developed to treat post-operative surgical pain and reduce the need for opioids. This Phase IIb clinical trial is the first in a series of MERIT… Read More

#News

#Clinical trials #Covid-19 #Data #Funding #Therapeutics

Appili Therapeutics secures $3.5 million in funding

Appili Therapeutics has entered into a $3.5 million convertible security funding agreement with Lind Global Fund. The company intends to use the funding to advance the broader Appili pipeline, including ATI-2307, a novel clinical stage antifungal expected to enter Phase II study in 2022. It will also support the operations… Read More

#News

#Clinical trials #Drug development #Lipidomics

Phase II clinical trial of ASC40 approved for acne treatment

Ascletis Pharma has announced that China National Medical Products Administration (NMPA) has approved the Phase II clinical trial application of ASC40 for the treatment of patients with moderate to severe acne. The Phase II trial is a randomised, double-blind, placebo-controlled, multicentre clinical trial to be conducted in China to evaluate… Read More

#News #Trending News

#Cell therapy #Clinical trials #Covid-19 #Drug development #Drug discovery #Drug targets #Stem cells #Therapeutics

Exploring iPSCs for individual and population health applications

Listen to this article on the DDW Podcast: Brad Hamilton, Founder and Chief Science Officer at GoodCell examines the potential of induced Pluripotent Stem Cells. Across the world, patients suffering from heart failure, donor organ rejection and many other life-altering illnesses are struggling to combat the symptoms of their… Read More

#Editor's Choice #Exclusive Content #News

#Clinical trials #Research

Positive data for investigational P2X3 antagonist for refractory chronic cough

Evotec has been informed by Bayer about positive Phase IIb results from a clinical trial evaluating the efficacy and safety of the investigational P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic cough. The underlying molecule is a P2X3 receptor antagonist in Bayer’s clinical development pipeline originating from a… Read More

#News

#Clinical trials #Gene editing #Gene mutation #Gene therapy #Genetics / genomics #Research

Exploring gene-based medicine’s true potential

Listen to this article on the DDW Podcast: By Christopher Doyle, PhD, Director, IBC Services at WCG The Covid-19 pandemic spawned a flurry of research that culminated in the development of several vaccines that express viral proteins from recombinant or synthetic genetic material. The success of these new vaccines… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News

#Clinical trials #Diabetes #Research #Type 2 diabetes

Preclinical data on oral polymer-based duodenal exclusion therapy

Glyscend has presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, from a study of its proprietary oral polymer duodenal exclusion therapy. The positive data were presented ahead of Glyscend’s Phase I clinical trials, which have commenced recruiting healthy subjects in South Australia. Glyscend is developing a… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Clinical trials #Drug discovery

Insilico Medicine discovers preclinical candidate for kidney fibrosis using AI

Insilico Medicine has announced today that its AI-powered drug discovery platform has delivered a preclinical candidate for kidney fibrosis. The preclinical candidate has desirable pharmacological properties and pharmacokinetic profile and has demonstrated highly promising results in in-vitro and in-vivo preclinical studies. Insilico Medicine is working to advance this program to… Read More

#News

Cancer research
#Cancer #Cancer research #Cell therapy #Clinical trials #Oncology

The personal touch: the scientist making an impact in cancer research

Listen to this article on the DDW Podcast: At 33, Martyn Hiscox is an inspiration to scientists in oncology research. Principal scientist with Adaptimmune, a UK cell therapy biotech, Lu Rahman uncovers Hiscox’s passion, dedication and the personal reason for developing cell therapy treatments for cancer. Hiscox clearly has… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Clinical trials #Drug development #Drug discovery #Infectious diseases #mRNA #Novel therapeutics #Oncology #Research

This week in drug discovery (2-6 August)

News round-up by DDW’s Megan Thomas for 2-6 August This week has seen results released, research continued, and clinical trial phases completed. DDW’s Megan Thomas has rounded up her top five stories showing promise in the drug discovery industry. Cardiac patients receiving nasal gel showed reduction of S. aureus… Read More

#News #Trending News

#Clinical trials #Comment #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

From the editor: Staying focused

The drug discovery sector is amazing, says Lu Rahman. And while we have witnessed that on a global scale throughout the pandemic, we should also recognise some of the equally-outstanding non-Covid related developments that have recently taken place. There is, in my opinion, no better industry to be part of at the… Read More

#Covid-19 #Editor's Choice #Exclusive Content #News #Opinion

#Clinical trials #Covid-19 #Moderna #mRNA #Therapeutics

Moderna doses first patient with its IL-2 mRNA therapeutic candidate

Moderna has dosed the first patients in the Phase I study of mRNA-6231, the company’s mRNA-encoded IL-2, modified for the expansion of regulatory T cells. mRNA-6231 is Moderna’s first autoimmune candidate to enter the clinic and its first subcutaneously administered therapeutic program. “The initiation of the Phase I study of… Read More

#News #Trending News